Diagnostic products

The current medical practice based on late-stage detection and standardized treatments is under scrutiny. There is a great need for introducing early, personalized and more specific diagnostic tools in order to improve the reversibility of diseases and reduce healthcare costs. In ORYZON, we develop and commercialize diagnostic products, more efficient, to promote early detection of certain diseases.

Therapy

In our internal R&D programs, we have identified NEW PHARMACOLOGICAL TARGETS for cancer and neurodegenerative disorders. In the small molecules field we are specialized in EPIGENETIC TARGETS. In addition, we have programs for the development of monoclonal antibodies.

Technology and services

We have a long tradition to collaborate with pharma and agrofood industry offering advanced R&D services including: genomic and proteomic analysis, bioinformatics, biomarker and target validation, crystallography and molecular modeling, fragment screening and a wide range of biological assays. Our ISO9001 quality system is the best guarantee for the quality of our services.

Investors

Founded in 2000, ORYZON is one of the pioneers in the Spanish Biotech field. A compelling equity history with several successful funding rounds, one product in the market a highly experienced Executive Management, more than 8 years of track record of recurrent revenues, and a patent portfolio with more than 50 International patent applications make of Oryzon a good opportunity for investors interested in the field.